abstract |
The present invention provides therapeutic and diagnostic methods and compositions for cancer, such as non-small cell lung cancer (NSCLC). The invention relates to a method of treating NSCLC, a method of determining whether a patient suffering from NSCLC is likely to respond to a treatment comprising a PD-L1 axis binding antagonist, a PD of a patient suffering from NSCLC Based on methods for predicting responsiveness to treatments containing L1-axis binding antagonists and the expression levels of biomarkers of the invention (eg, PD-L1 expression levels in tumor cells and / or tumor infiltrating immune cells) A method of selecting a therapy for an afflicted patient is provided. [Selection figure] None |